August 16, 2022 04:48 PM EDT
R&D
Pharma

Ab­b­Vie calls off PhI tri­al for I-Mab’s CD47 days af­ter Zai Lab shelves its own pro­gram

Kyle LaHucik

Senior Reporter

The CD47 field ran in­to an­oth­er hur­dle Tues­day as I-Mab qui­et­ly dis­closed in an SEC fil­ing that Ab­b­Vie is say­ing good­bye …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times